Trials / Completed
CompletedNCT05288504
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Avalo Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of AVTX-002 compared with placebo in patients with poorly controlled non-eosinophilic asthma (NEA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVTX-002 | Dose of 600 mg administered subcutaneously three times during the study. |
| DRUG | Placebo | Placebo sourced as normal saline administered subcutaneously three times during the study. |
Timeline
- Start date
- 2022-02-24
- Primary completion
- 2023-05-11
- Completion
- 2023-05-11
- First posted
- 2022-03-21
- Last updated
- 2024-09-05
- Results posted
- 2024-09-05
Locations
24 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05288504. Inclusion in this directory is not an endorsement.